AV-001
Phase 2Small molecule
AV-001 is one of 32 small molecule programs targeting Pneumonia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Plaquenil
Jazz PharmaceuticalsPreclinical
Innohep
Jazz PharmaceuticalsPreclinical
Zantac 150
CChattem
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Mucinex
RReckitt Benckiser LLC
Preclinical
Cancidas
FFresenius Kabi Taiwan Ltd.
Preclinical
Salbutamol
GSKPreclinical
Gantanol
CConrado Roberto Hoffmann Filho
Preclinical
AV-001
VVasomune Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AV-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVasomune Therapeutics, Inc.